This drug class ensures increased efficiency

If the figures hold true, the market will exhibit a positive CAGR of 5.V. North America Leads Global Market, Asia Pacific to Exhibit Fastest CAGRRegionally, North America accounted for a dominant share of 38.5 bn Globally by 2023.Transparency Market Research Report Added "Inhalation and Nasal Spray Generic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023".The rising incidence of respiratory diseases such as COPD and asthma, the increasing population of geriatrics, and the advent of an increasing number of generics manufacturers in the market will boost the global inhalation and nasal spray generics market. Of these, the combinations segment dominated the market for inhalation and nasal spray generic drugs, accounting for a share of 38. The segment is also likely to exhibit the fastest CAGR between 2015 and 2023., Beximco Pharmaceuticals, include Mylan N. Teva Pharmaceutical Industries Ltd.5% between 2015 and 2023. The company offers a broad portfolio and enjoys widespread market presence, which has substantially aided its lead in the market.8% in 2014.Inhalation and Nasal Spray Generic Drugs Market Expected to Reach US$35. The growing prevalence of COPD, asthma, and other respiratory disorders in North America has led to the expansion of the market in the region. held the leading position, accounting for a share of 15.3 bn by the end of 2023.8% in the market in 2014.

This drug class ensures increased efficiency and better compliance to pharmaceutical regulations, due to which it Trigger Sprayers Manufacturers witnesses a high demand globally.5% in the market in 2014.Combinations Segment Dominated the Market Based on Drug ClassIn terms of drug class, the inhalation and nasal spray generic drugs market is segmented into bronchodilators, corticosteroids, decongestant sprays, antihistamines, and combinations.html.3% of the market in 2014.com/inhalation-nasal-spray-generic-drugs. The segment will continue to dominate the market in the near future due to the rising incidence of asthma, fuelled by excessive use of tobacco and rising pollution level worldwide.8 bn, is anticipated to reach US$35.transparencymarketresearch. In the near future, however, Asia Pacific is likely to emerge as the most lucrative market for nasal spray and inhalation generic drugs. Furthermore, severe lung damage due to respiratory infections may also lead to asthma, which in turn fuels demand from the global inhalation and nasal spray generic drugs market.transparencymarketresearch. Asthma Emerged As Largest Application SegmentBased on application, the market for generic drugs in inhalation and nasal spray can be classified into allergic rhinitis, COPD, asthma, and others (such as influenza, cystic fibrosis). Of these, the asthma segment held 55.

Get a Free Sample Report. Other prominent players operating in the global market for inhalation and nasal spray generic drugs are Nephron Pharmaceuticals Corporation, Allergan plc, Roxane Laboratories, Inc., Ranbaxy Laboratories Ltd. The region is likely to exhibit a CAGR of 6. The market in the region is also capitalizing on the growing inclination of patients and their families towards affordable generic drugs. Dominates Global Market Intense competition prevails in the global inhalation and nasal spray generic drugs market.php?flag=S&rep_id=1922According to a recent report released by Transparency Market Research, the global market for inhalation and nasal spray generic drugs, which in 2014 stood at US$21., and Cipla Ltd. The generic drugs market for inhalation and nasal spray in Asia Pacific will witness rising demand due to the presence of a large population base, the increasing disposable incomes of people living in the region, and growing awareness pertaining to the benefits of generic drugs. The looming patent expiry of blockbuster drugs catering to this niche pharmaceutical segment will also help the market for their generic alternatives between 2015 and 2023. Sandoz International GmbH has emerged as the second largest enterprise in the market, offering a plethora of nasal spray and inhalation generic drugs.3% between 2015 and 2023. Among the leading companies operating therein, Teva Pharmaceutical Industries Ltd.Full Research Report on Global Inhalation and Nasal Spray Generic Drugs Market.

Megosztás a facebookon